IMNM

15.6905.54%
PT

Philip Tsai

Chief Technical Officer

Dr. Philip Tsai, also known as Phil, is Chief Technical Officer of Immunome, Inc. since June 2024. Dr. Tsai has nearly three decades of experience in product development, process optimization and manufacturing, particularly in the area of antibody-drug conjugates (ADCs). Prior to joining Immunome, Dr. Tsai spent 21 years at Seagen and then Pfizer (following the acquisition of Seagen in December 2023) in positions of increasing responsibility. Most recently, he was the SVP of Technical Development, responsible for end-to-end development of biologics and drug-linker manufacturing processes, analytics and drug products. Over the past two decades, he led a productive CMC development organization to advance Seagen's pipeline, including commercialization of its products. Dr. Tsai began his biotech career at Biogen, where he spent seven years optimizing biologics manufacturing processes. Dr. Tsai earned his M.S. degree and a PhD in Chemical Engineering with a minor in Biology from California Institute of Technology and a B.S. degree from the University of Illinois, Champaign Urbana.

Positions